Skip to main content
. Author manuscript; available in PMC: 2018 Jul 30.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Sep;55(1):39–48. doi: 10.1097/QAI.0b013e3181da1287

FIGURE 3.

FIGURE 3

Changes in lipid values over the first 96 weeks of therapy by treatment group. The graph shows the mean change from baseline to week 96 in total cholesterol, HDL-cholesterol, LDL-cholesterol, and TG in mg/dL between the raltegravir group (left column) and the efavirenz (right column). All 4 between-group comparisons were significantly different (P ≤ 0.001). The mean change in the total cholesterol:HDL-cholesterol ratio did not significantly differ between the raltegravir group (−0.18) and efavirenz group (0.04) (P = 0.192). HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride.